AleraCare and PURE Healthcare have announced plans to merge, aiming to establish a major ambulatory infusion platform with over 75 outpatient locations across 14 US states.
A merger agreement has been signed in this regard, though financial terms have not been disclosed.
The combined entity intends to enhance patient care, boost clinical outcomes, and expand access to cost-effective infusion services. This aligns with the goal of reducing overall healthcare expenditures.
AleraCare, founded in 2019, offers infusion and speciality pharmacy services through over 30 centres across the US. It collaborates closely with physicians, payors, and pharmaceutical entities to deliver infusion therapies in easily accessible locations.
The company targets high-need and complex medical cases.
Founded in 2018 by BUILD Capital Partners, PURE Healthcare focuses on making infusion therapy more accessible and affordable. It treats chronic and autoimmune conditions such as Alzheimer’s and multiple sclerosis through its Pure Infusion Suites, which span 43 locations in 14 states.
These suites are said to emphasise patient comfort and cost reduction while facilitating administrative processes for referring providers.
PURE Healthcare also operates speciality clinics like Memory Treatment Centers and Montana Arthritis Centers, prioritising partnerships with payer organisations and efficient patient authorisations.
The two firms stated: “The proposed merger creates an unprecedented opportunity to provide high-quality patient care, improve clinical outcomes and enhance the availability of infusion services that lower the overall cost to the healthcare system overall.”
Legal counsel for AleraCare is provided by Holland & Knight, while Kunzler Bean & Adamson advised PURE Healthcare, with Cantor Fitzgerald as its financial adviser.
The merger is slated for completion in Q4 2025, pending standard conditions, including regulatory approvals under the Hart-Scott-Rodino Antitrust Improvements Act.
